Dr.NateNeph said:

The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

Ask again with the specifics and you will get a better answer than this one.

Dr.NateNeph said:

The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

Thank you for spelling out the reasoning rather than just the conclusion. Taking it to my next appointment.

Clinical perspective, offered as context rather than as advice. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

NurseLeah_Nash said:

The distinction that resolves most of these threads is between what is true on average and what is true for one person.

Adding a me-too, because a thread of one person's experience is not much use. Posting only so the count is not one.

NurseLeah_Nash said:

The distinction that resolves most of these threads is between what is true on average and what is true for one person.

Adding the part of the answer the thread has not reached. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.